Elecsys® sFlt-1/PlGF (Preeclampsia)

Short term prediction and aid in diagnosis of pre-eclampsia

Elecsys® sFlt-1/PlGF (Pre-eclampsia)

Short term prediction and aid in diagnosis of pre-eclampsia

Pre-eclampsia is a serious multi-system complication of pregnancy, occurring in 3 - 5 % of pregnancies, and it is one of the leading causes of maternal and perinatal morbidity and mortality worldwide.1-3

Pre-eclampsia is defined as new-onset of hypertension and proteinuria after 20 weeks of gestation. The clinical presentation of pre-eclampsia and subsequent clinical course of the disease can vary tremendously, making prediction, diagnosis and assessment of disease progression difficult.1-3

Angiogenic factors (sFlt-1 and PlGF) are proven to play an important role in the pathogenesis of pre-eclampsia and their concentrations in maternal serum are altered even before the onset of the disease making them a tool for prediction and aid in diagnosis of pre-eclampsia.1-3

Benefits

In a recent multicentre, prospective study – PROGNOSIS (Prediction of short-term outcome in pregnant women with suspected pre-eclampsia study) – the Elecsys sFlt-1/PlGF ratio test proved to be a helpful tool in ­enabling clinicians to exclude pre-eclampsia for 1 week with very high confidence, ­reassuring women suspected of having the disease that it is safe to go home.4,5

  • Elecsys sFlt-1 and PlGF immunoassays for pre-eclampsia are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical context4,5
  • The measurement of the Elecsys sFlt-1/PlGF ratio test enables clinicians to discharge women with the confidence that they will not develop pre-eclampsia within the next seven days, whilst ensuring those who need a high level of care receive it.4-7,14
  • Early and precise diagnosis of ­pre-eclampsia can lead to effective ­clinical management and improved ­outcome for both mother and child4-7

 

First trimester screening of Pre-eclampsia

 

The use of Elecsys PlGF in first trimester screening combined with the sFlt-1/PlGF ratio test as an aid in the diagnosis and short term prediction of PE, provides a complete solution for PE throughout pregnancy.

  • Early-onset PE can be predicted effectively based on screening models including PlGF as one of the components8
  • First-trimester screening of PE is important to proceed with prophylactic use of low-dose aspirin9-13
  • Identify women at high risk for PE with an algorithm including PlGF and subsequent administration of Aspirin may prevent preterm PE9-13
Elecsys® sFlt-1/PlGF (Preeclampsia)

Elecsys® sFlt-1

  • Assay time

    18 min

  • Sample material

    Serum

  • Sample volume

    20 μL

  • Measuring range

    10– 85,000 pg/mL

Elecsys® PlGF

  • Assay time

    18 min

  • Sample material

    Serum

  • Sample volume

    50 μL

  • Measuring range

    3 – 10,000 pg/mL

References

 

  1. Verlohren, S., et al. (2012). Am J Obstet Gynecol 206(1), e1-8
  2. Verlohren, S., et al. (2010). Am J Obstet Gynecol 202(161), e1-11
  3. Verlohren, S., et al. (2014). Hypertension 63(2), 346-352
  4. Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324
  5. Zeisler, H., et al. (2016). N Engl J Med 374(1), 13-22
  6. Hund, M., et al. (2015). Hypertens Pregnancy 34(1), 102-115
  7. Klein, E., et al. (2014). PLoS ONE 11(5), e0156013
  8. O’Gorman, N., et al. (2016). Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12
  9. Tsiakkas A., et al. (2016). Ultrasound Obstet Gynecol 47, 472–477 
  10. Poon, I., et al. (2009). Hypertension 53(5), 812-818;
  11. Poon, L. C., et al. (2014). Prenat Diagn 34(7), 618-627
  12. Akolekar, R., et al. (2011). Prenat Diagn 31, 66-74;
  13. Akolekar, R., et al. (2013). Fetal Diagn Ther 33(1), 8-15
  14. Cerdeira, A. S. et al. (2019). Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women with Suspected Preeclampsia: INSPIRE. Hypertension 74, 983–990